OrbiSeq-L
Early-stage lung cancer diagnosis in patients with indeterminate pulmonary nodules (IPNs)
Key Facts
About Orbit Genomics
Orbit Genomics is a private, pre-revenue diagnostics company pioneering the analysis of repetitive DNA through its AI-driven OrbiSeq™ platform. Its lead product, OrbiSeq-L, is a non-invasive blood test designed to accurately diagnose early-stage lung cancer in patients with indeterminate pulmonary nodules, aiming to replace invasive biopsies. Founded in 2018 as a collaboration between Dr. Harold 'Skip' Garner and Ventac Partners, the company is establishing a scalable genomic foundation with applications across oncology, cardiology, neurology, and longevity. It recently won a national startup competition and is building its team, including a new Laboratory Director, to advance its diagnostic pipeline.
View full company profile